Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia

The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.

Automated summary

We report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving into myeloid sarcoma and B precursor ALL, highlighting the potential sensitivity of this disease to ruxolitinib due to the constitutive activation of Janus Kinase 2.